CENTANY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CENTANY (CENTANY).
Mupirocin binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
| Metabolism | Not systemically metabolized; rapidly degraded in the skin. |
| Excretion | Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (85-90% renal); minor biliary/fecal elimination (<5%). |
| Half-life | 8-10 minutes in serum; prolonged to 15-20 minutes in patients with renal impairment. Clinical context: Rapidly cleared, infrequent dosing intervals (e.g., every 20 minutes during procedure). |
| Protein binding | Negligible (<5%); not bound to plasma proteins. |
| Volume of Distribution | Not applicable (local/topical application); minimal systemic absorption (Vd ~0.15 L/kg if systemically absorbed). |
| Bioavailability | Topical: Not systemically absorbed (bioavailability negligible); no oral/intravenous formulation. |
| Onset of Action | Topical: Rapid hemostasis within 1-3 minutes; Systemic (not applicable for topical use). |
| Duration of Action | Topical hemostatic effect persists for 2-4 hours. Clinical note: Applied until hemostasis achieved; not sustained systemically. |
| Molecular Weight | 500.62 |
Apply a thin layer to affected area twice daily for 10 days. For perioral dermatitis, apply once daily.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required. |
| Liver impairment | No dosage adjustment required. |
| Pediatric use | Apply a thin layer to affected area twice daily for 10 days. For children aged 2 months and older, same as adult dosing; safety and efficacy not established for infants under 2 months. |
| Geriatric use | No specific dose adjustment needed. Use with caution due to potential for increased systemic absorption in elderly with compromised skin barrier. |
| 1st trimester | No adequate studies in pregnant women; use only if clearly needed. |
| 2nd trimester | No evidence of fetal harm in animal studies; use with caution. |
| 3rd trimester | Avoid use near term due to potential risk of kernicterus in neonates. |
Clinical note
Comprehensive clinical and safety monograph for CENTANY (CENTANY).
| Placental transfer | Not studied in humans; animal studies show minimal placental transfer. |
| Breastfeeding | Mupirocin is poorly absorbed orally; systemic exposure to infant via breast milk is negligible. Considered compatible with breastfeeding. |
| Lactation Rating | L1 (Safe) |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to mupirocin or any component of CENTANY
| Precautions | For topical use only, Avoid contact with eyes, May cause local irritation or sensitization, Prolonged use may result in overgrowth of nonsusceptible organisms, Use with caution in renal impairment if applied to large areas of damaged skin |
| Food/Dietary | No known food interactions with topical mupirocin. Avoid oral ingestion of the ointment. |
| Clinical Pearls | CENTANY (mupirocin) is a topical antibiotic for impetigo due to Staphylococcus aureus or Streptococcus pyogenes. Avoid contact with eyes. Use only on small areas of skin; not for MRSA decolonization of nares (Bactroban nasal is different). Discontinue if irritation or sensitization occurs. Apply thin layer 3 times daily for 3-5 days. Do not use with other topical products without consulting. |
Loading safety data…
| Teratogenic Risk | CENTANY (mupirocin) is classified as Pregnancy Category B. No teratogenic effects observed in animal studies at systemic doses up to 100 times the human topical dose. However, due to limited human data, use during pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women. Risk to fetus cannot be ruled out. Systemic absorption is minimal after topical application, reducing fetal exposure. |
| Fetal Monitoring | No specific maternal or fetal monitoring required beyond routine prenatal care. Monitor for signs of local irritation or allergic reaction. If used on large areas of broken skin, monitor for systemic adverse effects (rare). |
| Fertility Effects | No studies on fertility effects in humans. In animal studies, no impairment of fertility was observed at doses up to 100 mg/kg subcutaneously (about 20 times human topical dose). No expected effect on fertility with topical mupirocin due to minimal systemic absorption. |
| Patient Advice | Apply a small amount to the affected area as directed, usually 3 times daily. · Wash hands before and after application. · Do not cover with bandage unless instructed. · Avoid getting in eyes, nose, mouth, or large body surfaces. · Use for the full prescribed duration even if symptoms improve. · Stop use and call doctor if rash, itching, or severe irritation occurs. |